Blue Bulls

“There will always be bull markets followed by bear markets followed by bull markets” - John Templeton.

[IRAN ARMY ☫ @IranArmySpoofX]

🟥 American actor Mel Gibson:

"If the world wants peace, it must unite against Israel."

[Stuart Hinds @hinds_stuart]

A few months back - the gateway to #Havieron 8.4 million Au ounce equivalent
ore body.
Hopefully some updates in the next quarterly so we shareholders can see what progress has been made

#GGP

[Avacta @avacta]

Avacta provides a business update ahead of today’s Annual General Meeting of Shareholders, reviewing progress across the portfolio in the first half of 2026 and outlining upcoming milestones. #AVCT https://t.co/9MRKfHT4AE

[Myles McNulty @MylesMcNulty]

Energy Fuels Announces Definitive Agreement to Acquire VAC for $1.9 Billion

Further huge news for the global rare earths industry, with $UUUU acquiring a leading ex-China NdFeB magnet manufacturer.

Once VAC's US magnet plant hits nameplate capacity (likely in H2), it'll be on an annualised EBITDA runrate of circa $100m. So it's being acquired at 19x forecast EBITDA, although not accounting for significant expansion potential.

EF now becomes a direct competitor to the existing two majors, $MP and $USAR, as the vertically integrated ex-China REE champion.

These players can all see the impending monster step change in global magnet demand, as humanoids, data centres and the space industry enjoy exponential growth.

For my own key REE holding, Mkango #MKA $MKA, when its Texas plant comes online in H2 next year, it will boast a slightly larger nameplate capacity than VAC (being 350 tpa in the UK, 350 tpa in Germany and 1,550 tpa in the US) - which should generate a cumulative annualized EBITDA of north of $100m.

This is another fantastic precedent transaction to highlight HyProMag's extreme undervaluation.

https://t.co/mCU3M9NgJo

[ʟᴀɴᴅᴏʀᴇ ʀᴇꜱᴏᴜʀᴄᴇꜱ ᴘʟᴄ @landore_plc]

In our May 2026 update:

- Why resource-backed juniors may offer the strongest upside.

- Lamaune infill sampling underway.

- Growing valuation disconnect across the sector.

- Landore positioned for the next phase.

Read more: https://t.co/g2A0ZFUefB

#LND #Gold #JuniorMining

[SON LAİK BÜKÜCÜ 🇹🇷 @TheLaikYobaz]

Dünyaca ünlü İspanyol teknik direktör Pep Guardiola:

“Filistin’deki soykırım canımı yakıyor. Etkilenmemek imkânsız.

Hiç konuşmamamı istiyorlar. Ben her zaman buradayım ve konuşacağım.”

Karakterli olmak paha biçilemez...

[Blue Bulls @BlueBullish]

@hughesy0707 Best of luck Richard

[Richard Hughes @hughesy0707]

Delighted to be appointed as chairman of #AVCT

My core priority is to ensure the value of preCISION is exploited to its fullest, for the benefit of all shareholders.

I am more than confident we have the team and the intellectual property to enable this.

[Keir Starmer @Keir_Starmer]

On Eid al-Adha, I send my warmest wishes to all those celebrating across the UK and around the world.

At this special time, I wish you and your loved ones peace, joy and good health.

May Eid bring comfort and inspire us all to continue standing together in the spirit of unity and mutual respect.

Eid Mubarak.

[Avacta @avacta]

Avacta is giving two presentations today at the American Association for Cancer Research (AACR) Annual Meeting 2026.  https://t.co/LuYgF4fNq8 #AVCT

[Myles McNulty @MylesMcNulty]

If in its now ongoing P1a/b trial, #AVCT $AVCT's AVA6103 can simply replicate the pre-clinical data already generated, I believe it is going to utterly dominate Enhertu and other leading antibody-drug conjugates on the market. Why?

1) Superior targeting =
a. greater efficacy, and
b. fewer and less severe side effects.

2) Far larger TAM (six diverse indications already being targeted in P1a/b, three of which (breast, colorectal, gastric / GEJ) are amongst the top 5 indications worldwide). A tumor agnostic juggernaut.

3) Substantially cheaper to manufacture (up to 90% cheaper, in fact, owing to no use of a biologic (mAb) in the 6103 molecule).

And to note: AVA6000 (Avacta's first clinical candidate, now almost 5 years into a P1a/b trial) has dramatically outperformed in clinic, over its pre-clinical data.

[Stuart Hinds @hinds_stuart]

Excellent news from a fantastic team. Two bits of additional news. 1/ BlackRock upped its position today in an RNS release. 2/ The #Havieron EPA approval has moved closer to being approved. @paddygall1 has the details

[Iranian Force @MrImranPk]

Retweet if you believe Netanyahu is a war criminal.

[NADA 𓂆 @nadaa01012]

NEVER STOP TALKING ABOUT PALESTINE!!!

[Greatland @Greatland_GGP]

Hear from our MD @shaun_day_ in person or via the livestream Q&A on 16 April at the London $GGP Town Hall Meeting. Submit your questions here: https://t.co/x0WMAgkonJ

Register to attend: https://t.co/mpb8RoDc15

[Cristiano Ronaldo @Cristiano]

Good to be back! 😎 Looking good 👍🏽

[Stuart Hinds @hinds_stuart]

What makes this even more compelling is our partnership with @Greatland_GGP The joint venture covers a significant 200.8Km2 land package
#GGP
#TelferHub

https://t.co/6oqOfh5orT

[Vox Markets @VOXmarkets]

Cadence secures funding for Sonora Lithium arbitration

@CadenceMinerals #KDNC #Lithium

https://t.co/cuoOTXgGGi

[Samuel @SamueILFC]

Arne Slot out. Just sack him.

[Leo Drizzy Drake @drakedewoo1]

@Cristiano Eid Mubarak
Jummah Mubarak 🥰